ScripScan:Suven Life Sciences Ltd
code:530239
Cmp:14
Story:Partnership business model with Innovator Drug Companies.Partnering development of under patent molecules.Partnering drug discovery and development of New Chemical Entities with global drug majors.Partnering with multinationals for contract manufacturing.Leveraging relationships with 25 global life science companies.Offering a clear value proposition to multinationals in cutting costs,time to market and outsourcing research capabilities.Successful transformation in supplying products from grams to tons.The company was very much in the limelight recently. The stock has recovered from its recent low of 15rs. The spike up in the stock was after the company announced that its has received four product patent approvals - three from Australia and one from New Zealand, which could be used for treating various central nervous disorders.These patents are valid through 2027. With these new patents, the company now has eleven patents from Australia and twelve from New Zealand. Financially, the company did not do well in Q1FY12. Though the company showed a rise in net income for the quarter at Rs.44.63 crore v/s Rs.35.92 crore in Q1FY11, its net profit showed a decline of 2.32% at Rs.3.36 crore. On an equity of Rs.11.67 crore, this Re.1 face value stock has an annualized EPS of Rs.1.16 and this discounts the current price by 13 times.One shouldnt expect huge returns till the company reports robust numbers.At present its a hold.
